PureTech Health plc (LON:PRTC - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as GBX 138 ($1.70) and last traded at GBX 143 ($1.76), with a volume of 1221521 shares trading hands. The stock had previously closed at GBX 140 ($1.72).
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group reaffirmed a "buy" rating and issued a GBX 455 ($5.60) target price on shares of PureTech Health in a research note on Monday, December 16th.
Check Out Our Latest Stock Report on PureTech Health
PureTech Health Stock Up 2.1 %
The company has a debt-to-equity ratio of 47.27, a current ratio of 3.68 and a quick ratio of 2.51. The company has a market capitalization of £342.37 million, a PE ratio of -621.74 and a beta of 1.02. The business's 50 day simple moving average is GBX 161.30 and its 200 day simple moving average is GBX 162.91.
About PureTech Health
(
Get Free Report)
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Further Reading
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
